Simplify Logo
Sanofi

Sanofi

Global pharma company; vaccines and R&D

Associate Director - Strategic Pricing

Full-TimeDeadline 10/1/26
$148.5k - $214.5k/yr
Senior
Bachelor's, Master's, MBA
Cambridge, MA, USA+1 more

More locations: Morristown, NJ, USA

Hybrid

Global hybrid work policy applies; occasional attendance at live meetings is required. Travel is approximately 10%–20%.

About the job

Requirements
  • A bachelor's degree is required.
  • At least 5 years of pharmaceutical industry experience is required; consulting or equivalent experience is also considered.
  • Basic knowledge of the United States healthcare system and reimbursement environment, including market access customers and channels, is required.
  • Strong written and verbal communication skills and executive presence are required.
  • Excellent analytical skills are required.
  • Strong organizational skills with meticulous attention to detail and auditable accuracy are required.
  • The ability to manage multiple projects, priorities, and timelines is required.
  • Advanced ability to use common analytical and communications tools, including PowerPoint, Excel, and Access, is required.
  • The ability to travel to key meetings and conventions and meet with matrix partners in Cambridge, Massachusetts, or Bridgewater, New Jersey, as needed, is required.
Responsibilities
  • Support brand pricing initiatives for the General Medicines business unit and advise Brand Access Strategy Teams in developing list price, market access, and contracting strategies.
  • Collaborate with peers and United States and global leaders across Market Access, Pricing, Contract Operations, Contract Development, Account Management, Trade, Finance, Business Intelligence, Data Management, Forecasting, Business Insights, Market Access Shared Services, Government Affairs, Internal Auditing, Internal Controls, and Processes.
  • Provide stakeholders and senior management with relevant pricing and reimbursement information, support, and recommendations.
  • Partner with United States and Global Headquarters Access Strategy teams to help design United States-specific pricing and market access strategies for inline products and products in development.
  • Assist deal teams on Commercial, Government, Provider, and Institutional customer bids and offers, ensuring alignment with brand strategy and profitability.
  • Design and develop pricing models to evaluate the impact of pre-launch and post-launch strategies, including Average Sales Price, Average Manufacturer Price, and Best Price.
  • Model the impact of life-cycle pricing strategies and legislative measures on revenue.
  • Support Brand Financial and Gross-to-Net projections by providing insight into current market dynamics and future market events.
  • Assist with the approval and execution of list price changes.
  • Travel approximately 10%–20% to support the team and internal stakeholders, matrix partners, customers, and company or industry meetings.
Desired Qualifications
  • An MBA or Master of Science in Administration degree.
  • Experience in a pricing capacity or relevant experience in Contract Development, Government Pricing and Operations, Channel Payer Gross-to-Net Analysis, and Deal Negotiations.
  • Understanding of contract modeling, data sources used in modeling, the Gross-to-Net projections process, and implications for brand profit and loss.
  • Understanding of drug pricing, including First Databank and/or Medi-Span data sources.
  • Knowledge of and experience working with government pricing calculations, including Average Manufacturer Price, Best Price, and Average Sales Price pricing dynamics.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 sales rose 13.6%, while launches grew 49.6% and Dupixent 30.8%.
  • July 2026 FDA approval expanded Sarclisa across all U.S. myeloma indications.
  • Paulo Fontoura assumed R&D leadership on September 1, 2026, accelerating pipeline execution.

What critics are saying

  • Tolebrutinib’s FDA rejection on December 24, 2025 exposed severe liver-injury risk.
  • Dupixent lawsuits consolidated in New Jersey by June 2026 threaten label and damages exposure.
  • Sanofi’s insulin plant needed €400 million German aid on September 8, 2026, signaling supply fragility.

What makes Sanofi unique

  • Dupixent posted €4.17 billion Q1 2026 sales, dominating immunology globally.
  • Sanofi’s July 2026 Sarclisa Escena became the first cancer on-body injector treatment.
  • Sanofi secured Cenrifki EU approval in June 2026, advancing a differentiated MS franchise.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

La Croix
Sep 8th, 2026
EU approves $448M German subsidy to Sanofi for insulin production security

The European Commission has approved a €400 million subsidy from Germany to pharmaceutical company Sanofi to maintain its Frankfurt insulin production site. The Commission stated that without this aid, Sanofi would close the German facility, reducing insulin supply security across the European Economic Area. The subsidy aims to compensate Sanofi for costs related to a service of general economic interest, strengthening insulin supply resilience for German patients. In return, Sanofi must build a new insulin factory in Frankfurt by 31 December 2032 and guarantee minimum annual production of 1.1 tonnes until 2042. Sanofi is among the world's leading insulin producers. The company announced in 2024 a €1.3 billion investment in Frankfurt to construct a new complex replacing existing facilities.

StreetInsider
Aug 25th, 2026
Altesa BioSciences wins award for oversubscribed $75M Series B to advance COPD therapies

Atlanta-based Altesa BioSciences has won the 2026 Georgia Life Sciences Golden Helix Award for Deal of the Year, recognising its oversubscribed $75 million Series B financing round. The funding, led by Forbion with participation from Sanofi, Medicxi, Pitango, and Atlantic Partners, will advance the clinical-stage pharmaceutical company's lead therapy, vapendavir. Vapendavir is an investigational oral treatment for chronic lung diseases including COPD and asthma. The drug is currently being evaluated in the Phase 2b CARDINAL trial, which will enrol 900 COPD patients across the US and UK. The Georgia Research Alliance Venture Fund was an early investor in Altesa. The company's scientific founders previously helped develop molnupiravir, one of the earliest COVID-19 treatments.

Business Wire
Aug 13th, 2026
Epicrispr Biotechnologies Closes $90 Million Oversubscribed Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Epicrispr Biotechnologies Closes $90 Million Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Morningstar
Aug 12th, 2026
InduPro raises $77M Series B, doses first patient in Phase 1 trial of bispecific ADC for lung cancer

InduPro has closed a $77 million Series B financing round and dosed its first patient in a Phase 1 study of IDP-001, its lead oncology programme. The biotechnology company is developing IDP-001, a bispecific antibody-drug conjugate targeting EGFR and a novel tumour-associated proximity antigen, for treating advanced squamous non-small cell lung cancer and other solid tumours. The Column Group led the financing round, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective, Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and Company. Proceeds will support Phase 1 clinical development and early proof-of-concept data generation for IDP-001, whilst advancing InduPro's broader preclinical pipeline. InduPro uses a proximity-guided platform to map protein spatial relationships on cell surfaces for discovering selective co-target pairs.

FinancialContent
Jul 24th, 2026
Scribe Therapeutics prices upsized $129M IPO at top of range

Scribe Therapeutics, a clinical-stage biotechnology company developing in vivo CRISPR technologies, has priced its upsized initial public offering at $15.00 per share, the high end of its range. The company is offering 8,580,000 shares, expecting to raise $128.7 million in gross proceeds before fees and expenses. Scribe has also granted underwriters a 30-day option to purchase up to 1,287,000 additional shares. The shares are expected to begin trading on the Nasdaq Global Market on 24 July 2026 under the ticker symbol "SCTX", with the offering closing on 27 July 2026. Additionally, Scribe has agreed to sell 500,000 shares at the same price to Sanofi in a concurrent private placement. Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo Securities are serving as joint book-running managers.